---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-141380"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:08:20.798573+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Galera Therapeutics Q1 net loss $17.7M; avasopasem NDA gets FDA priority review with PDUFA Aug 9

## Summary
- Net loss of $17.7M ($0.50 per share) in Q1 2023 vs $15.4M ($0.58 per share) in Q1 2022.
- Cash, cash equivalents and short-term investments of $47.8M as of March 31, 2023; expected to fund operations into Q4 2023.
- FDA granted priority review for avasopasem NDA for radiotherapy-induced severe oral mucositis; PDUFA date August 9, 2023.
- Raised $30M gross proceeds from registered direct offering in February 2023.
- Expanded commercial leadership team with three new VPs in preparation for potential U.S. launch.

## SEC filing metadata
- accession: 0001193125-23-141380
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312523141380/0001193125-23-141380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312523141380/d476140d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-141380
- JSON: https://secwatch.observer/filing/0001193125-23-141380.json
- Plain text: https://secwatch.observer/filing/0001193125-23-141380.txt

## Key facts
- Earnings Releases
  Galera Therapeutics, Inc. reported financial results for quarter ended March 31, 2023.
  - Period: quarter ended March 31, 2023
  - Result: reported results
  source text: On May 11, 2023, Galera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312523141380/0001193125-23-141380-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.